Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen’s osteoporosis treatment offers BMD hope

Amgen’s osteoporosis treatment offers BMD hope

21st May 2008

Bone density is increased in post-menopausal women who take Denosumab rather than continuing with alendronate, a study suggests.

Amgen’s head-to-head, double blind trial of this group of women, who displayed low bone mass, showed “superior results”, it said.

The phase III study, undertaken for a year, saw patients injected twice with subcutaneous injections of denosumab and the bone mass density (BMD) of their total hip, lumbar spine, femoral neck, distal radius and hip trochanter.

These measurements were compared against results of another who continued on alendronate and revealed an 80 per cent improvement, based on the total hip measurement alone.

Executive vice-president of research and development Roger M Perlmutter said: “Particularly important was the finding that in this population that had previously been treated with alendronate, patients transitioned to denosumab achieved greater BMD gains than those continuing on alendronate therapy.”

The government’s health advisory body, the National Institute for Health and Clinical Excellence, estimates a third of women over 50 are to risk from vertebral fracture and one in six will break a hip.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.